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Background: Both hyperglycaemia and dendritic cells (DCs) play causative roles in atherosclerosis. However,
whether they interact in atherosclerosis remains uncertain. Therefore, we examined whether high glucose could
regulate the expression of scavenger receptors responsible for oxidised low-density lipoprotein (oxLDL) uptake in
DCs, a critical step in atherogenesis. In addition, we investigated the impact of glucose on DC maturation regarding
changes in phenotype and cytokine secretion.
Methods: Immature DCs were cultured with different concentrations of glucose (5.5 mmol/L, 15 mmol/L, 30 mmol/L)
in the absence or presence of N-acetylcysteine (NAC), SB203580 or Bay11-7082 for 24 hours. We used 30 mmol/L
mannitol as a high-osmolarity control treatment. The expression of the scavenger receptors SR-A, CD36 and LOX-1 was
determined by real-time PCR and western blot analysis. Furthermore, DCs were incubated with DiI-labelled oxLDL. The
DiI-oxLDL-incorporated fraction was investigated by flow cytometry analysis. The intracellular production of ROS in DCs
was measured by dichlorodihydrofluorescein (DCF) fluorescence using confocal microscopy. Finally, flow cytometry
analysis was used to investigate immunophenotypic protein expression (CD83 and CD86). Supernatant cytokine
measurements were used for immune function assays.
Results: The incubation of DCs with glucose enhanced, in a dose-dependent manner, the gene and protein
expression of SR-A, CD36 and LOX-1. This effect was partially abolished by NAC, SB203580 and Bay11-7082. Incubation
of DCs with mannitol (30 mmol/L) did not enhance these scavenger receptors’ expression. High glucose upregulated
the production of ROS and expression of p38 MAPK in DCs. NAC partially reversed p38 MAPK upregulation. High
glucose increased the oxLDL-uptake capacity of DCs. Blockage of the scavenger receptors SR-A and CD36 reduced
oxLDL uptake, but blockage of LOX-1 did not. Furthermore, high-glucose (15 mmol/L or 30 mmol/L) treatment
increased CD86 and CD83 in DCs. High glucose also increased IL-6 and IL-12 secretion and decreased IL-10 secretion.
Conclusion: High glucose can increase the expression of the scavenger receptors SR-A, CD36 and LOX-1, which can
increase the oxLDL-uptake capacity of DCs. High glucose induces a proinflammatory cytokine profile in human DCs,
leading to DC maturation. These results support the hypothesis that atherosclerosis is aggravated by hyperglycaemia-
induced DC activation and oxLDL uptake.
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Cardiovascular complications remain the leading cause
of mortality in adults with diabetes. Hyperglycaemia
is the hallmark of diabetes and is a major independent
risk factor for diabetic macrovascular disease, playing a
key pathogenic role in the development of diabetes-
associated atherosclerosis [1-3]. However, a clear causa-
tive role for hyperglycaemia has not been established.
The major biochemical pathways of hyperglycaemic vas-
cular damage and the hyperglycaemia-induced activation
of nuclear transcription factor-kappa B (NF-κB) result
from a single common mechanism: overproduction of
reactive oxygen species (ROS) [4]. The overproduction
of ROS in poorly controlled diabetes could contribute to
endothelial and vascular dysfunction, leading to athero-
sclerosis. Recent studies in animal models indicate that
glucose may play a role in diabetes-accelerated athero-
sclerosis by promoting pro-inflammatory responses in
monocytes and macrophages [5].
Atherosclerosis is a chronic inflammatory vessel dis-
ease characterised by early endothelial dysfunction. In
response to endothelial activation, monocytes and T-
cells mediate the progression of atherosclerosis. Den-
dritic cells (DCs) are a specific type of leukocyte that
alert the immune system to the presence of antigens, in-
fections and inflammatory mediators. They play a central
role in the initiation of both innate and adaptive im-
mune responses [6]. In recent years, the impact of DCs
on the initiation and progression of atherosclerosis has
been evaluated [7]. DCs home to the vessel wall and rec-
ognise foreign and autoantigens (viral and bacterial anti-
gens, oxidised LDL (oxLDL), HSP 60/65) [8,9]. oxLDL
uptake might result in enhanced presentation of lipid
and peptide antigens to NKT and T-cells and further
stimulate vascular inflammation and adhesion of mono-
cytes in the atherosclerotic plaque9. Scavenger receptors,
which are expressed by macrophages and monocyte-
derived DCs, are major receptors for oxLDL. The stimula-
tion of DCs by oxLDL through binding to scavenger
receptors leads to their activation and can be accompanied
by enhanced cytokine production [10]. Furthermore, al-
though lipid uptake and foam cell formation in the artery
have been attributed mostly to macrophages, recent stud-
ies have demonstrated that DCs in the subendothelial
space of the aorta can also efficiently accumulate lipids
and differentiate into foam cells, thereby contributing to
the initiation and further progression of atherosclerosis
[11]. SR-A, CD36 and LOX-1 are essential scavenger
receptors for uptake of oxLDL and foam cell formation.
Elevated glucose can increase the expression of scav-
enger receptors CD36 [12], SR-A [13] and LOX-1 [14] in
macrophages, thereby contributing to diabetes and its
related disease atherosclerosis. However, to the best of
our knowledge, little is known about how glucose affectsthe expression of scavenger receptors in DCs. Therefore,
we examined whether high glucose regulates scavenger
receptor expression in DCs, focusing on CD36, SR-A
and LOX-1, and whether glucose modulates the matur-
ation processes of DCs. In addition, we analysed the




Human CD14+ immunomagnetic microbeads were
obtained from Miltenyi Biotech GmbH (Bergisch-
Gladbach, Germany). Recombinant human granulocyte/
macrophage colony-stimulating factor (rhGM-CSF),
recombinant human interleukin-4 (rhIL-4), enzyme-
linked immunosorbent assay (ELISA) kits for IL-6, IL-10,
IL-12p70 and tumour necrosis factor-α (TNF-α) were
from R&D Systems. (United States).Histopaque-1077,
D-glucose, N-acetyl cysteine (NAC) and FITC-dextran
were from Sigma. Trizol reagent was from Invitrogen
(United States). The reverse-transcription system and
GoTaq qPCR Master Mix were from Promega (United
States). The human T-cell recovery immunocolumn kit
was from Cedarlane Laboratories Ltd. Goat anti-human
SR-A polyclonal antibody and mouse anti-human CD36
monoclonal antibody were from Santa Cruz Biotechnol-
ogy. Rabbit anti-human LOX-1 polyclonal antibody was
from Abcam. Mouse anti-human CD83-FITC, CD86-
FITC and HLA-DR-FITC antibodies were from BD
Pharmingen. DiI-oxLDL was purchased from Peking
Union-Biology Co. Ltd. DCFH-DA was purchased from
Molecular Probes (United States). Bay11-7082 was pur-
chased from Merck (United States).
Generation of monocyte-derived dendritic cells
Peripheral blood mononuclear cells (PBMCs) were
obtained from healthy volunteers. Briefly, blood was
diluted 1:2 in PBS layered over Histopaque 1077 and
centrifuged for 30 min at 2000 rpm at room
temperature. The interface was recovered and washed
three times in PBS. CD14+ PBMCs were purified by
using CD14+ immunomagnetic micro beads and incu-
bated in RPMI-1640 medium supplemented with GM-
CSF (100 ng/mL) and IL-4 (50 ng/mL) in six-well tissue
culture plates at 37°C and an atmosphere of 5% CO2.
The medium was replaced every 2 days. On day six, cells
were exposed to glucose at various concentrations
(5.5 mmol/L, 15 mmol/L, 30 mmol/L) for a further 24 h.
In control experiments, mannitol was added to the
medium to bring total osmolality to a value equivalent
to 30 mmol/L glucose (high glucose). In some experi-
ments, 10 mmol/L NAC, 10 μmol/L SB203580 or
10 μmol/L Bay11-7082 was added simultaneously with
high glucose.
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The mRNA expression of the different scavenger recep-
tors (SR-A, CD36 and LOX-1) in DCs was analysed
using real-time quantitative reverse transcription–poly-
merase chain reaction (RT-PCR). Total RNA was iso-
lated and treated with DNase using a Trizol Reagent kit
according to the manufacturer’s instructions. Five micro-
grams of the total RNA sample was reverse-transcribed
using oligo-dT and SuperScript III. SR-A was amplified
using the sense primer 5′-TCCTCGTGTTTGCAGTT
CTC-3′ and antisense primer 5′-GCAATTCTTCGT
TTCCCACT-3′. CD36 was amplified using the sense
primer 5′-CGCTGAGGACAACACAGTCT-3′ and anti-
sense primer 5′-GTTGTCAGCCTCTGTTCCAA-3′.
LOX-1 was amplified using the sense primer 5′-GGGCT
CATTTAACTGGGAAA-3′ and antisense primer 5′-
GAAATTGCTTGCTGGATGAA-3′. Quantitative PCR
using SYBR Green reagent was performed on the ABI
7500 Real-time PCR System (Applied Biosystems, United
States). Gene expression was analysed by the system
software, and the copies of each mRNA molecule were
determined by the standard curve method.
Western blotting
After treatment with glucose, DCs were washed with
ice-cold PBS and were then lysed in cold cell lysis buffer.
Protein concentration was measured using a BCA Pro-
tein Assay Reagent kit (Beyotime Institute of Biotechnol-
ogy). Protein extracts (20 μg) were separated by 7.5%
SDS-PAGE, transferred to a nitrocellulose membrane
by electrotransfer (200 V for 30–60 min) and blocked
with 5% nonfat milk for 1 h at room temperature. Anti-
gen–antibody complexes were detected using an appro-
priate HRP-labelled secondary antibody with the ECL
detection system (Thermo Fisher Scientific, Rockford,
IL, USA) according to the manufacturer’s protocol. The
resulting bands were analysed densitometrically using
ImageQuant software (Molecular Dynamics, Sunnyvale,
CA, USA). All values were normalised to the tubulin
loading control.
oxLDL uptake
After treatment with 5.5 mmol/L or 30 mmol/L glucose
for 24 h, DCs were incubated with DiI-labelled oxLDL
(10 μg/ml) for 60 min at 37°C. Then, cells were
harvested and washed three times at 4°C. The DiI-
oxLDL-incorporated fraction was quantified by flow
cytometry analysis.
Blocking oxLDL uptake
DCs were incubated with DiI-oxLDL (10 μg/ml) for 4 h
at 4°C with or without anti-SR-A (Biozol, USA), anti-
CD36 (Abcam, USA) and anti-LOX-1 (R&D Systems,
USA) neutralizing antibodies. The endocytosed DiI-oxLDL fraction was analysed using flow cytometry ana-
lysis. To rule out nonspecific blocking, control IgG anti-
bodies were used.
Measurement of intracellular reactive oxygen species
After 24 h incubation with high-glucose medium, the
ROS probe dye DCFH-DA (10 μmol/L) was added.
Intracellular production of ROS in DCs was measured
by dichlorodihydrofluorescein (DCF) fluorescence using
confocal laser-scanning microscopy (Zeiss Axiovert 135
microscope, Leica TCs-SP2 confocal attachment, laser
excitation 488 nm, emission long-pass LP515-nm filter
set). Images of all samples were collected by single rapid
scans under identical parameters, such as contrast and
brightness. Four groups of 20 cells for each sample were
randomly selected from the image, and fluorescence
intensity was measured. The relative fluorescence inten-
sities are the average values of all experiments.
Flow cytometric measurement
On culture day 7, cells were washed and resuspended
in ice-cold PBS containing 5% foetal bovine serum
to prevent nonspecific binding, then incubated with
FITC-conjugated mAbs (CD83-FITC, CD86-FITC) for
30 minutes at 4°C. Then, the cells were analysed using a
flow cytometer (BD Biosciences) and Cell Quest soft-
ware. Cells stained with the appropriate isotype-matched
Ig were used as negative controls.
DC cytokine secretion
The supernatants of human DC culture (±24 h incuba-
tion with different concentrations of glucose) were
harvested and stored at −80°C until they were analysed
for the presence of IL-6, IL-10, IL-12p70 and TNF-α.
These cytokines were determined using cytokine-
specific ELISA kits according to the manufacturer’s
instructions.
Statistical analysis
Data are presented as the mean ± standard deviation of
the mean (SDM). Group mean values were compared
with 1-way analysis of variance followed by post hoc
tests using the Tukey procedure for pairwise compari-
sons. All in vitro experiments were repeated at least
three times with different cells. All statistical analyses
were performed with SPSS for Windows 13.0. P values
less than 0.05 were considered statistically significant.
Results
Effects of glucose on SR-A, CD36 and LOX-1 mRNA
expression in DCs
We first studied the effects of different concentrations
of glucose on the expression of the SR-A, CD36 and
LOX-1 genes in DCs. As shown in Figure 1, the
Figure 1 Effects of glucose on the mRNA expression of SR-A, CD36 and LOX-1 in DCs. SR-A, CD36 and LOX-1 mRNAs were analysed by
real-time quantitative RT-PCR. Representative examples of the dose-dependent expression of SR-A, CD36 and LOX-1 on DCs. Mean ± SEM. n = 3.
*p < 0.05 vs. 5.5 mmol/L glucose, **p < 0.01 vs. 5.5 mmol/L glucose.
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LOX-1 mRNA expression were dose-dependent, with
the maximal effects occurring at 30 mmol/L glucose.
The incubation of DCs with mannitol (30 mmol/L)did not enhance these scavenger receptors’ mRNA ex-
pression, suggesting that the upregulation of scaven-
ger receptors by high glucose is not due to the
osmotic effect.
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expression in DCs
The changes observed at the protein level were similar
to those described for mRNA. Incubating DCs for
24 hours with increasing glucose concentrations (5.5 to
30 mmol/L) enhanced, in a dose-dependent manner,
SR-A, CD36 and LOX-1 protein expression. SR-A, CD36
and LOX-1 protein levels normalised to the level of
tubulin are illustrated in Figure 2. No stimulatory effect
of mannitol (30 mmol/L) on SR-A, CD36 or LOX-1
protein expression was observed (Figure 2).oxLDL uptake and blockage of scavenger receptors
As SR-A, CD36 and LOX-1 are high-affinity scavenger
receptors for oxLDL, we next examined the effects of
glucose on uptake of DiI-labelled oxLDL by DCs. When
the cells were treated with 30 mmol/L glucose, an in-
crease of more than twofold in the uptake of oxLDL wasFigure 2 Effects of glucose on SR-A, CD36 and LOX-1 protein express
blotting. Densitometric analysis showed significantly increased expression o
Mean ± SEM. n = 3. *p < 0.05 vs. 5.5 mmol/L glucose, **p < 0.01 vs. 5.5 mmoobserved compared to 5.5 mmol/L glucose-treated cells,
as assessed by flow cytometric analysis (Figure 3).
The uptake of oxLDL was partially inhibited by spe-
cific blockage with antibodies against SR-A and CD36.
Anti-SR-A reduced oxLDL uptake by 45%, anti-CD36 by
66% (p < 0.01 for all experiments), but anti-LOX-1 did
not lead to a reduced oxLDL uptake (p = 0.24) (Figure 4).
Furthermore, nonspecific control IgG-antibodies did not
affect oxLDL uptake (data not shown).
Effects of high glucose on the production of ROS in DCs
To examine whether high glucose induces ROS produc-
tion in cultured human monocyte-derived DCs, we mea-
sured intracellular ROS using the redox-sensitive
fluorescent dye DCFH-DA. The fluorescence intensity
was significantly higher in DCs cultured for 24 hours in
high-glucose medium (30 mM glucose) compared with
those in normal glucose (5.5 mM glucose). A representa-
tive microscopic scan is shown in Figure 5A, and dataion in DCs. SR-A, CD36 and LOX-1 proteins were analysed by western
f SR-A, CD36 and LOX-1 after prestimulation by 30 mmol/L glucose.
l/L glucose.
Figure 3 Effects of glucose on the uptake of DiI-oxLDL by DCs. Representative example of the effects of 5.5 mM Glu and 30 mM Glu on the
uptake of DiI-oxLDL by DCs at 37°C.
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Figure 5B. These results suggest that high glucose can in-
duce the formation of ROS in human monocytes-derived
DCs.
Signalling pathways involved in high glucose-induced
DCs scavenger receptor expression
To identify the signalling pathways involved in the
stimulatory effect of high glucose on scavenger receptor
expression, DCs were pretreated for 2 hours with the
p38 mitogen-activated protein kinase (MAPK) inhibitor
SB203580 (10 μmol/L) or the NF-κB inhibitor BAY 11-
7082(10 μmol/L) before exposure to glucose. As shown
in Figures 6 and 7, at both the mRNA and protein levels,Figure 4 Blocking the uptake of DiI-oxLDL by DCs. Representative histo
CD36 and LOX-1 at 4°C. 30 mM Glu: 30 mmol/L glucose.SB203580 partially abrogated glucose-induced SR-A,
CD36 and LOX-1 expression. A similar effect was
observed when the cells were pre-incubated with BAY
11–7082 (Figures 6 and 7). Because diabetes and high
glucose induce increased oxidative stress, we next deter-
mined the role of oxidative stress in the regulation of
scavenger receptor expression by glucose. As shown in
Figures 6 and 7, the pre-incubation of DCs with the
antioxidant N-acetyl-L-cysteine (NAC) (10 mmol/L)
prevented the stimulatory effect of high glucose on SR-A,
CD36 and LOX-1 expression.
We next assessed the sequential events leading to
glucose-induced p38 MAPK activation. Figure 8
shows that high glucose activated the phosphorylationgrams of blocking DiI-oxLDL uptake using antibodies against SR-A,
Figure 5 Effect of high glucose on reactive oxygen species production in DCs. Reactive oxygen species production was visualised by DCF
fluorescence confocal laser microscopy. A, Representative microscopic scan. B, Quantification of reactive oxygen species production. Data analysis
of 4 separate experiments, expressed as relative fluorescence. Mean ± SEM, *p < 0.01 vs. 5.5 mmol/L glucose. DIC: differential interference
contrast microscopy.
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glucose was blocked in the presence of SB203580
(Figure 8). Furthermore, the glucose-induced activa-
tion of p38 MAPK was reduced by NAC (Figure 8).
Altogether, these results demonstrate that high glu-
cose stimulation activated the p38 MAPK pathway
and via ROS generation.Effects of glucose on DCs maturation
Mature DCs express many co-stimulatory molecules,
such as CD83 and CD86. Flow cytometric analysis
showed that the expression of CD83 and CD86 in
15 mmol/L and 30 mmol/L glucose-treated DCs in-
creased significantly compared with normal glucose
(5.5 mmol/L), and this effect was dose-dependent (Figure 9).
These results indicate that high glucose could promote the
maturation of DCs. Mannitol at the same osmolality as
high glucose did not increase the expression of CD83 or
CD86 (Figure 9), suggesting that the acceleration of the
maturation process by high glucose is not due to the
osmotic effect.Effects of glucose on DCs cytokine secretion
Mature DCs secrete a wide spectrum of cytokines and
chemokines. We examined the influence of glucose (5.6
or 30 mmol/L) on the secretion of IL-6, IL-10, IL-12p70
and TNF-α from DCs by ELISAs. IL-6 (+40%; p < 0.05)
and IL-12p70 secretion (+50%; p < 0.05) were increased
significantly, and IL-10 was decreased by 38.7% (p < 0.05),
whereas TNF-α (+2.2%) was not significantly affected by
glucose (Figure 10).Discussion
The present study demonstrates that glucose enhanced,
in a dose-dependent manner, the expression of the DC
scavenger receptors SR-A, CD36 and LOX-1, both at the
mRNA and protein levels. This phenomenon was
suppressed by a p38 MAPK inhibitor, an NF-κB inhibi-
tor and an antioxidant. Our observation that high glu-
cose enhanced DC ROS generation provides strong
evidence for a crucial role of ROS in high glucose-
induced scavenger receptor upregulation. We also found
that the antioxidant and p38 MAPK inhibitor blocked
glucose-induced p38 MAPK activation. Taken together,
these results indicate that the increased production of
intracellular ROS and the activation of p38 MAPK
pathways are initial signalling events in the regulation
of scavenger receptor expression by glucose that are
required for subsequent activation of NF-κB. We
also found that glucose promoted DCs’ ability to
take up oxLDL. This capability was partially blocked
by neutralising antibodies against CD36 and SR-A,
but not LOX-1. Moreover, high glucose induced a
proinflammatory cytokine profile in human DCs and
triggered DC maturation. To our knowledge, this is
the first study showing these important effects of
glucose on DCs.
Cardiovascular diseases in patients with type 2 diabetes
are a large and increasing health problem. Unfortunately,
the exactly mechanisms leading to atherosclerosis in dia-
betes are only partially understood. Quite recently, Skov V
et al. [15] reported that dysregulated gene interactions and
pathways in the cells of the arterial wall in diabetes may
play important roles in the arterial response to injury and
Figure 6 Effects of p38 MAPK inhibitor, NF-κB inhibitor and NAC on glucose-induced scavenger receptors mRNA levels. DCs were
pretreated for 2 hours with SB203580, NAC or BAY 11–7082 before exposure to high glucose. SR-A, CD36 and LOX-1 mRNAs were quantified by
real-time PCR. Mean ± SEM. n = 3. *p < 0.05 vs. 5.5 mmol/L glucose, #p < 0.05 vs. 30 mmol/L glucose.
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glycaemia in type 2 diabetes mellitus are associated with a
systemic proinflammatory state that promotes the devel-
opment of atherosclerosis [16]. Our recent in vitro studies
have shown that advanced glycosylation end products
(AGEs) [17] and hyperinsulinaemia [18] enhance DC mat-
uration and induce antigen-specific T-cell activation. DCs
and oxLDL accumulate in progressive atherosclerotic
plaque. In the subendothelial space, DCs phagocytose
antigens such as oxLDL. Then, DCs can either accumulate
in the arterial wall and/or migrate to draining lymph
nodes for antigen presentation [19]. Lipid and oxLDLuptake might result in the enhanced presentation of lipid
and peptide antigens to NKT and T-cells. Furthermore,
some foam cells can derive from DCs, and the oxLDL
uptake capacity of DCs is reflected by the expression of
SR-A, CD36 and LOX-1 [10]. The engulfment of lipid by
resident intimal DCs and differentiation into foam cells is
possibly one of the earliest steps of atherogenesis [20]. In
addition, CD36 mediates oxLDL-induced TLR4/TLR6
activation [21]. oxLDL stimulates DCs by binding to
CD36 and TLR4, leading to DC activation, which can
be accompanied by enhanced cytokine production [22].
The present study shows that high glucose can mediate
Figure 7 Effects of p38 MAPK inhibitor, NF-κB inhibitor and NAC on glucose-induced scavenger receptors protein levels. DCs were
pretreated for 2 hours with SB203580, NAC or BAY 11–7082 before exposure to high glucose. SR-A, CD36 and LOX-1 protein levels were
quantified by western blotting. Mean ± SEM. n = 3. *p < 0.05 vs. 5.5 mmol/L glucose, #p < 0.05 vs. 30 mmol/L glucose.
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related to initiation and progression of atherosclerosis in
diabetes patients.
High glucose induced an increased endocytic function
of DCs, which was determined by a semiquantitative
method using a fluorescence-labelled ligand (DiI-OxLDL).
This effect was partially but significantly inhibited by an
anti-CD36 or anti-SR-A neutralising antibody, suggesting
some contribution of CD36 and SR-A to atherosclerosis
formation by human DCs under diabetic conditions.
However, the anti-LOX-1-neutralising antibody did not
show significant inhibition of the endocytosis of DiI-
oxLDL by high glucose-treated DCs. The reason may be
that LOX-1 is mainly an endothelial-specific scavenger
receptor, and although it is also expressed on DCs, macro-
phages, smooth muscle cells and platelets, its expression
level is relatively low in these cell types [23-26]. Therefore,
it is likely that LOX-1 is not a major receptor responsible
for the uptake of oxLDL in DCs. Further studies are
needed to determine the exact contribution of LOX-1 tohigh glucose-induced upregulation of DCs in vitro. The
relative contributions of CD36, SR-A and LOX-1 to the
diabetes-induced enhancement of foam cell and athero-
sclerosis formation by DCs has to be clarified by future
studies.
The effects of several inhibitors on high glucose-
enhanced scavenger receptor expression were examined
to determine the signalling pathway between glucose
stimulation and scavenger receptor expression. High
glucose-enhanced scavenger receptor expression was
suppressed by the p38 MAPK inhibitor, NF-κB inhibitor
and antioxidant. Hyperglycaemia-induced oxidative
stress is implicated in the pathogenesis of chronic dia-
betic complications. Recent studies [12-14] found that
ROS generated by glucose in macrophages may be key
intermediates in the regulation of SR-A, CD36 and
LOX-1 expression by this metabolic factor. Moreover,
Farhangkhoee H et al. [27] found that high glucose-
induced upregulation of CD36 may be involved in in-
creased oxidative stress in microvascular endothelial cell.
Figure 8 Inhibitory effects of NAC and SB203580 on p38 MAPK
phosphorylation in glucose-stimulated DCs. DCs were pretreated
for 2 hours with SB203580 or NAC before exposure to high glucose.
Then, cells were harvested and assayed for the phosphorylation of
p38 MAPK by western blots. Mean ± SEM. n = 3. *p < 0.05 vs.
5.5 mmol/L glucose, #p < 0.05 vs. 30 mmol/L glucose.
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hanced ROS generation in DCs. Evidence linking
glucose-induced oxidative stress with activation of p38
MAPK in macrophages supports a role for this kinase in
the control of scavenger receptor expression by hyper-
glycaemia [4,28]. In line with these hypotheses, we found
that antioxidant and p38 MAPK inhibitor abolished
glucose-induced scavenger receptor expression, implicat-
ing ROS and kinases as signalling molecules mediating
this effect of glucose. Our data also indicate a role for
oxidative stress in p38 MAPK activation. Finally, weFigure 9 The immunophenotypic expression of DCs exposed to differ
performed to estimate cell-surface CD83 and CD86 expression. 5.5 mM Glu
30 mmol/L glucose; mannitol: 30 mmol/L mannitol.found that NF-κB inhibitor suppressed glucose-induced
scavenger receptor expression. So we propose that high
glucose induces DCs to generate ROS and activate p38
MAPK signalling, which leads to the subsequent activa-
tion of NF-κB and finally upregulates scavenger receptor
expression. But Takaki KF et al. [13] reported that p38
MAPK inhibitor have no effect on high glucose-induced
SR-A expression in macrophages, which is different from
our present study. We do not know the reason for the
discrepancy at present. One possible reason is that
Takaki KF et al. used monocyte-derived macrophages
whereas we used monocyte-derived DCs. The difference
in cell types might cause different results.
In this study, we focussed not only on the impact of
glucose on scavenger receptors but also on DC activa-
tion. In doing so, we investigated the influence of glu-
cose on DC maturation and cytokine production. CD86
and CD83 are mature markers of DCs. Co-stimulation
by the ligand CD86 and its receptor CD28 is required
for efficient T-cell stimulation [9]. We found that glu-
cose induced the upregulation of the co-stimulatory re-
ceptors CD86 and CD83, which supports the hypothesis
that T-cells are activated by DCs in plaque lesions [29].
Consistent with this study, our recent in vivo study [30]
also showed that the expression of CD86 was signifi-
cantly increased in diabetes patients with unstable an-
gina pectoris(UAP), which indicated that the functional
status of DCs in diabetic patients with UAP were more
mature and activated than none diabetic patients with
UAP. The inflammatory activation of DCs is reflected
by the differentially expressed cytokine-chemokine
spectrum induced by glucose. We discovered that the
pro-atherosclerotic chemokines IL-6 and IL-12 are
induced by high glucose, while the release of anti-
atherosclerotic IL-10 is reduced. IL-10 may have thera-
peutic potential in various inflammatory diseases,ent concentrations of glucose. Flow cytometric analysis was
: 5.5 mmol/L glucose; 15 mM Glu: 15 mmol/L glucose; 30 mM Glu:
Figure 10 Cytokine secretion in high glucose-treated DCs. DCs of different groups were harvested, and the supernatants were collected; IL-6,
IL-10, IL-12p70 and TNF-α were determined using commercially available ELISAs. *p < 0.05 vs. 5.5 mmol/L glucose. Mean ± SEM. n = 3.
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induced foam cell formation and apoptosis in macro-
phages and endothelial cells. The inhibitory effect of IL-10
on oxLDL-induced apoptosis was partially dependent
on reduced p38 MAPK phosphorylation [31]. IL-6 is a
pro-atherogenic cytokine that is locally produced by
plaque-infiltrating inflammatory cells [32]. IL-12 en-
hances the ability of activated human monocytes to
oxidise LDL and is able to modify the chemokine pro-
duction of human vascular smooth muscle cells [33].
IL-12 also seems to be important for both Th1 differen-
tiation within the plaque and for overall T-cell recruit-
ment into the plaque [34]. Considering that DCs are
most frequently observed in atherosclerotic lesions
enriched with T-cells, the increased expression of
costimulatory molecules on DCs and cytokine secretion
induced by high glucose suggest that activation of DCs
in diabetes patients is an important mediator in
immuno-inflammatory process, as DCs are responsible
for T-cell activation, and this cellular interaction plays
a role in plaque instability and vulnerability, leading to
rupture.
Conclusion
In summary, high glucose can increase the expression of
scavenger receptors SR-A, CD36 and LOX-1 on DCs,
which can lead to uptake of oxLDL and maturation of
DCs. Mature, oxLDL-presenting DCs are essential for
priming naive T-cells, thereby inducing an oxLDL-
specific T-cell line. (Auto-)Immune-active T-cells are an
essential element of the inflammation cascade. This
effect is mediated by enhancing ROS generation andsignalling via the p38 MAPK and NF-κB pathways. The
results of the present study show that one of the mecha-
nisms by which high glucose promotes atherogenesis in-
volves its effects on DCs. These findings may be relevant
in understanding the intracellular signalling associated
with the pathophysiological processes involved in the
growth and destabilisation of atherosclerotic plaques in
diabetes patients and provide new pharmacological
targets to prevent the development and progression of
diabetic complications.
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